M A Eisenberger
Overview
Explore the profile of M A Eisenberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Halabi S, Dutta S, Tangen C, Rosenthal M, Petrylak D, Thompson Jr I, et al.
Ann Oncol
. 2020 Apr;
31(7):930-941.
PMID: 32289380
Background: We have shown previously in multivariable analysis that black men had 19% lower risk of death than white men with metastatic castration-resistant prostate cancer (mCRPC) treated with a docetaxel...
2.
Nakazawa M, Lu C, Chen Y, Paller C, Carducci M, Eisenberger M, et al.
Ann Oncol
. 2015 Jun;
26(9):1859-1865.
PMID: 26117829
Background: We previously showed that pretreatment detection of androgen receptor splice variant-7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer is associated with resistance to abiraterone...
3.
van Soest R, Templeton A, Vera-Badillo F, Mercier F, Sonpavde G, Amir E, et al.
Ann Oncol
. 2014 Dec;
26(4):743-749.
PMID: 25515657
Background: The neutrophil-to-lymphocyte ratio (NLR), a marker of host inflammation, has been associated with poor outcome in several solid tumors. Here, we investigated associations of the derived NLR (dNLR) and...
4.
Paller C, Olatoye D, Xie S, Zhou X, Denmeade S, Eisenberger M, et al.
Prostate Cancer Prostatic Dis
. 2013 Oct;
17(1):28-33.
PMID: 24100642
Background: PSA doubling time (PSADT) is an attractive intermediate end point for assessing novel therapies in biochemically recurrent prostate cancer (BRPC). This study explores whether PSADT calculations are influenced by...
5.
Schweizer M, Zhou X, Wang H, Yang T, Shaukat F, Partin A, et al.
Ann Oncol
. 2013 Aug;
24(11):2881-6.
PMID: 23946329
Background: Clinical trials in men with biochemically recurrent prostate cancer (BRPC) have been hampered by long survival times, making overall survival (OS) a difficult end point to reach. Intermediate end...
6.
Morris M, Eisenberger M, Pili R, Denmeade S, Rathkopf D, Slovin S, et al.
Ann Oncol
. 2012 May;
23(10):2714-2719.
PMID: 22553195
Background: This first-in-human phase I/IIA study was designed to evaluate the safety and pharmacokinetics (PKs) of AGS-PSCA a fully human monoclonal antibody directed to prostate stem cell antigen (PSCA) in...
7.
Carducci M, Gilbert J, Bowling M, Noe D, Eisenberger M, Sinibaldi V, et al.
Clin Cancer Res
. 2001 Oct;
7(10):3047-55.
PMID: 11595694
Purpose: Sodium phenylbutyrate (PB) demonstrates potent differentiating capacity in multiple hematopoietic and solid tumor cell lines. We conducted a Phase I and pharmacokinetic study of PB by continuous infusion to...
8.
Walsh P, DeWeese T, Eisenberger M
J Urol
. 2001 Jul;
166(2):508-15; discussion 515-6.
PMID: 11458056
Purpose: We present a structured debate supporting the premise that immediate hormonal intervention has not been conclusively shown to provide a survival advantage in the management of advanced prostate cancer....
9.
Kucuk O, Fisher E, Moinpour C, Coleman D, Hussain M, Sartor A, et al.
Urology
. 2001 Jul;
58(1):53-8.
PMID: 11445479
Objectives: To determine the efficacy and tolerability of bicalutamide in patients with advanced prostate cancer with progression after conventional hormonal therapy. Methods: Fifty-two patients received bicalutamide, 150 mg once daily,...
10.
Schroder L, Lew D, Flanigan R, Eisenberger M, Seay T, Hammond N, et al.
Urol Oncol
. 2001 Jun;
6(4):145-148.
PMID: 11418320
Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4...